|
以腹水为主要表现的多中心型Castleman病的诊治分析
|
Abstract:
Castleman病是一种临床和病理与淋巴瘤相似的少见的淋巴增殖性疾病,其特征包括弥漫性淋巴结肿大、脾肿大、贫血、血小板增多、高球蛋白血症、血清炎性因子升高和全身炎症反应。由于该病的临床表现缺乏特异性,因此必须依靠病理学改变进行确诊,免疫组织化学染色标记可进一步明确诊断及分型。本研究报告了多中心型Castleman病患者伴有大量腹水的临床特点及诊疗策略,并进行了相关鉴别诊断的分析,为Castleman病的诊断提供了线索。在临床实践中,当患者出现全身性淋巴结肿大、伴有大量浆膜腔积液、少尿、低蛋白血症等广泛全身表现时,应根据临床表现进一步进行淋巴组织病理活检,以避免误诊或漏诊。
Castleman’s disease is a rare lymphoproliferative disorder that mimics lymphoma clinically and pathologically, characterized by diffuse lymphadenopathy, splenomegaly, anemia, thrombocytosis, hyperglobulinemia, elevated serum inflammatory factors, and systemic inflammatory responses. Due to the lack of specificity of the clinical manifestations of the disease, the diagnosis must be confirmed by pathologic changes, and immunohistochemical staining markers can further confirm the diagnosis and classification. This study reported the clinical characteristics and diagnosis and treatment strategies of patients with multicenter Castleman disease with massive ascites, and analyzed the relevant differential diagnoses, which provided clues for the diagnosis of Castleman disease. In clinical practice, when patients have extensive systemic manifestations such as generalized lymphadenopathy, large serous effusion, oliguria, and hypoproteinemia, further lymphoid histopathological biopsy should be performed according to the clinical manifestations to avoid misdiagnosis or missed diagnosis.
[1] | van Rhee, F., Oksenhendler, E., Srkalovic, G., Voorhees, P., Lim, M., Dispenzieri, A., et al. (2020) International Evidence-Based Consensus Diagnostic and Treatment Guidelines for Unicentric Castleman Disease. Blood Advances, 4, 6039-6050. https://doi.org/10.1182/bloodadvances.2020003334 |
[2] | van Rhee, F., Voorhees, P., Dispenzieri, A., Fosså, A., Srkalovic, G., Ide, M., et al. (2018) International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease. Blood, 132, 2115-2124. https://doi.org/10.1182/blood-2018-07-862334 |
[3] | González García, A., Fernández-Martín, J. and Robles Marhuenda, Á. (2022) Idiopathic Multicentric Castleman Disease and Associated Autoimmune and Autoinflammatory Conditions: Practical Guidance for Diagnosis. Rheumatology, 62, 1426-1435. https://doi.org/10.1093/rheumatology/keac481 |
[4] | Munshi, N., Mehra, M., van de Velde, H., Desai, A., Potluri, R. and Vermeulen, J. (2014) Use of a Claims Database to Characterize and Estimate the Incidence Rate for Castleman Disease. Leukemia & Lymphoma, 56, 1252-1260. https://doi.org/10.3109/10428194.2014.953145 |
[5] | Suda, T., Katano, H., Delsol, G., Kakiuchi, C., Nakamura, T., Shiota, M., et al. (2001) HHV‐8 Infection Status of Aids‐unrelated and Aids‐Associated Multicentric Castleman’s Disease. Pathology International, 51, 671-679. https://doi.org/10.1046/j.1440-1827.2001.01266.x |
[6] | van Rhee, F., Wong, R.S., Munshi, N., Rossi, J., Ke, X., Fosså, A., et al. (2014) Siltuximab for Multicentric Castleman’s Disease: A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Oncology, 15, 966-974. https://doi.org/10.1016/s1470-2045(14)70319-5 |
[7] | Abramson, J.S. (2019) Diagnosis and Management of Castleman Disease. Journal of the National Comprehensive Cancer Network, 17, 1417-1419. https://doi.org/10.6004/jnccn.2019.5037 |
[8] | Wu, D., Lim, M.S. and Jaffe, E.S. (2018) Pathology of Castleman Disease. Hematology/Oncology Clinics of North America, 32, 37-52. https://doi.org/10.1016/j.hoc.2017.09.004 |
[9] | Boutboul, D., Fadlallah, J., Chawki, S., Fieschi, C., Malphettes, M., Dossier, A., et al. (2019) Treatment and Outcome of Unicentric Castleman Disease: A Retrospective Analysis of 71 Cases. British Journal of Haematology, 186, 269-273. https://doi.org/10.1111/bjh.15921 |
[10] | Dispenzieri, A. and Fajgenbaum, D.C. (2020) Overview of Castleman Disease. Blood, 135, 1353-1364. https://doi.org/10.1182/blood.2019000931 |
[11] | Zhang, L., Zhao, A., Duan, M., Li, Z., Cao, X., Feng, J., et al. (2019) Phase 2 Study Using Oral Thalidomide-Cyclophosphamide-Prednisone for Idiopathic Multicentric Castleman Disease. Blood, 133, 1720-1728. https://doi.org/10.1182/blood-2018-11-884577 |
[12] | 王永英, 李红玲, 邵香香, 等. 重型特发性多中心型Castleman病1例[J]. 中国现代医生, 2023, 61(18): 143-144. |
[13] | Farrukh, L., Lightle, A., Peredo-Wende, R. and Murawski, S. (2022) Case of Idiopathic Multicentric Castleman’s Disease: The Master Mimicker. BMJ Case Reports, 15, e250706. https://doi.org/10.1136/bcr-2022-250706 |
[14] | Liu, X. and Tian, M. (2022) Glucocorticoids Combined with Tofacitinib in the Treatment of Castleman’s Disease: A Case Report. World Journal of Clinical Cases, 10, 10794-10802. https://doi.org/10.12998/wjcc.v10.i29.10794 |
[15] | Zhu, X., Chen, S., Fang, F., Jia, Y. and Zhang, K. (2021) An Unusual Cause of Ascites: Castleman Disease. BMC Gastroenterology, 21, Article No. 477. https://doi.org/10.1186/s12876-021-02050-7 |
[16] | Kasinathan, G. and Sathar, J. (2021) Ascites as a Presenting Sign of Multicentric Mixed-Type Castleman Disease Variant of POEMS Syndrome. Hematology, Transfusion and Cell Therapy, 43, 222-225. https://doi.org/10.1016/j.htct.2020.01.007 |
[17] | 周爽, 李玥. Castleman病变异型POEMS综合征一例[J]. 协和医学杂志, 2020, 11(2): 202-206. |
[18] | 顾萌萌, 赵艳红, 王雨晴, 等. 伴有大量腹水的多中心型Castleman病1例[J]. 中华老年多器官疾病杂志, 2018, 17(11): 857-858. |
[19] | 胡明均, 刘瑜, 杨婷, 等. Castleman病伴腹水及肾功能损害1例报道并文献复习[J]. 数理医药学杂志, 2007, 20(1): 34-35. |
[20] | 江滔, 敖忠芳. 反应停治疗多中心Castleman’s病1例随访15年余[J]. 临床医药文献电子杂志, 2017, 4(40): 7774-7775. |
[21] | 张俊丽. 表现为腹腔积液及皮肤多发血管瘤样突起的Castleman病1例[J]. 现代医药卫生, 2013, 29(18): 2874. |
[22] | 程果. 病例报道: 以腹水为特征的Castleman病1例[D]: [硕士学位论文]. 杭州: 浙江大学, 2010. |
[23] | 刘全利, 穆长吉. 以顽固性腹水为特征的Castleman病1例[J]. 中国厂矿医学, 2008, 21(6): 765. |
[24] | 陈懿建, 张立群, 陈方平, 等. 多中心性透明血管型Castleman病2例诊治分析[J]. 实用医学杂志, 2007, 23(19): 3064-3066. |
[25] | 曹芝君, 张林, 吴叔明, 等. 以皮肤色素沉着、腹水为首发症状的Castleman病一例[J]. 中华消化杂志, 2003, 23(4): 44. |
[26] | Abarca, M., Andrade, R.J., García-Arjona, A., Escolar, J.L., Blanes, A., García-Hirschfeld, J.M., et al. (2000) Title. Digestive Diseases and Sciences, 45, 697-702. https://doi.org/10.1023/a:1005483308015 |
[27] | Saaresranta, T., Söderström, K.O. and Ruokonen, E.L. (1995) Chylothorax and Chylous Ascites as Symptoms of Cas-tleman’s Disease. Duodecim; laaketieteellinen aikakauskirja, 111, 348-350. |
[28] | Berson, A., Fabre, M., Buffet, C., et al. (1990) Unusual Cause of Ascites: The POEMS Syndrome. Gastroenterologie clinique et biologique, 14, 675-679. |
[29] | Mizutani, N., Okada, S., Tanaka, J., Minematu, S., Tobe, T., Midorikawa, O., et al. (1989) Multicentric Giant Lymph Node Hyperplasia with Ascites and Double Cancers, an Autopsy Case. The Tohoku Journal of Experimental Medicine, 158, 1-7. https://doi.org/10.1620/tjem.158.1 |
[30] | SéE, A., Cerf, M., Rigaud, D., et al. (1986) Treatment of an Abdominal Form of Castleman’s Disease by Chemotherapy. Annales de gastroenterologie et d’hepatologie, 22, 19-22. |